To investigate the effect of costimulatory factors in the pathogenesis of chronic idiopathic thrombocytopenic purpura(CITP), we examined the expression of CD80 on platelets and megakaryocytes in patients with CITP and...To investigate the effect of costimulatory factors in the pathogenesis of chronic idiopathic thrombocytopenic purpura(CITP), we examined the expression of CD80 on platelets and megakaryocytes in patients with CITP and the controls by FACS. By using CD80 monoclonal antibody (McAb) to inhibit interaction among cells which is mediated by costimulatory factors, we observed the effect of CD80 McAb on the growth and maturation of megakaryocytic progenitors of patients with CITP in vitro . The results showed the expression of CD80 on platelets and megakaryocytes in CITP group was significantly higher than that in controls ( P <0.01). There was a significantly positive correlation between the expression of CD80 on platelets and serum PAIgG in CITP (r=0.86, P <0.05). The mean of various clone numbers (CFU MK, BFU MK and mCFU MK) in CITP were all lower than those in controls ( P <0.05). In megakaryocytes co cultured with CD80 McAb, there was an increasing tendency of the number of CFU MK and big CFU MK (the number of megakaryocyte with GPⅢ a positive was more than 20) and mediate CFU MK (the number of megakaryocyte with GPⅢ a positive was 11-20). When the concentration of CD80 McAb was 10 μg/L, there was a significant difference in the number of megakaryocytic colony formation (CFU MK, BFU MK and mCFU MK) between the group with CD80 McAb and that without it ( P <0.05).These showed the abnormality of costimulatory factors had important effect in the pathogenesis of CITP.展开更多
目的考察幽门螺杆菌（Hp）在慢性特发性血小板减少性紫癜（CITP）患者中的感染情况，探讨针对Hp感染的CITP患者采用根除Hp治疗，是否有助于血小板的上升。方法通过检测CITP患者粪便Hp抗原（HpSA）和外周血HPIgG抗体，以确定是否有Hp感...目的考察幽门螺杆菌（Hp）在慢性特发性血小板减少性紫癜（CITP）患者中的感染情况，探讨针对Hp感染的CITP患者采用根除Hp治疗，是否有助于血小板的上升。方法通过检测CITP患者粪便Hp抗原（HpSA）和外周血HPIgG抗体，以确定是否有Hp感染。对确诊的有Hp感染的CITP患者在其原治疗方案基础上加用根除Hp治疗（奥美拉唑20mg＋克拉霉素0．5g＋阿莫西林1．0g，1日2次×1周），比较治疗前后血小板数量。结果34例CITP患者中有Hp感染20例，感染率58．82％。20例患者中，成功根除Hp11例，根除率55％。成功根除Hp的11例患者治疗前后的血小板统计学比较有差异（17．00±5．13×10^9／L，vs26．38±7．96×10^9／L，P=0．011）；未成功根除Hp的9例患者治疗前后血小板数量在统计学比较上无差异（26．10±13．93×10^9／L vs 51．85±39．28×10^9／L，P=0．138）。给予根除Hp治疗的20例患者中，治疗有效病例16例（80％），无效4例（20％）。根除Hp治疗有效患者中血小板开始上升的时间为3—28d，中位时间为6d；维持有效的时间为17—125d，中位时间为75d。结论本临床观察中，CITP患者合并Hp感染率为58．82％，采用根除Hp治疗的根除率为55％，根除Hp治疗有助于Hp感染的CITP患者血小板恢复。展开更多
基金Theprojectwassupportedbya grantforreturnedscholarsfromtheMinistryofEducation (No .6 - 74 )
文摘To investigate the effect of costimulatory factors in the pathogenesis of chronic idiopathic thrombocytopenic purpura(CITP), we examined the expression of CD80 on platelets and megakaryocytes in patients with CITP and the controls by FACS. By using CD80 monoclonal antibody (McAb) to inhibit interaction among cells which is mediated by costimulatory factors, we observed the effect of CD80 McAb on the growth and maturation of megakaryocytic progenitors of patients with CITP in vitro . The results showed the expression of CD80 on platelets and megakaryocytes in CITP group was significantly higher than that in controls ( P <0.01). There was a significantly positive correlation between the expression of CD80 on platelets and serum PAIgG in CITP (r=0.86, P <0.05). The mean of various clone numbers (CFU MK, BFU MK and mCFU MK) in CITP were all lower than those in controls ( P <0.05). In megakaryocytes co cultured with CD80 McAb, there was an increasing tendency of the number of CFU MK and big CFU MK (the number of megakaryocyte with GPⅢ a positive was more than 20) and mediate CFU MK (the number of megakaryocyte with GPⅢ a positive was 11-20). When the concentration of CD80 McAb was 10 μg/L, there was a significant difference in the number of megakaryocytic colony formation (CFU MK, BFU MK and mCFU MK) between the group with CD80 McAb and that without it ( P <0.05).These showed the abnormality of costimulatory factors had important effect in the pathogenesis of CITP.
文摘目的考察幽门螺杆菌（Hp）在慢性特发性血小板减少性紫癜（CITP）患者中的感染情况，探讨针对Hp感染的CITP患者采用根除Hp治疗，是否有助于血小板的上升。方法通过检测CITP患者粪便Hp抗原（HpSA）和外周血HPIgG抗体，以确定是否有Hp感染。对确诊的有Hp感染的CITP患者在其原治疗方案基础上加用根除Hp治疗（奥美拉唑20mg＋克拉霉素0．5g＋阿莫西林1．0g，1日2次×1周），比较治疗前后血小板数量。结果34例CITP患者中有Hp感染20例，感染率58．82％。20例患者中，成功根除Hp11例，根除率55％。成功根除Hp的11例患者治疗前后的血小板统计学比较有差异（17．00±5．13×10^9／L，vs26．38±7．96×10^9／L，P=0．011）；未成功根除Hp的9例患者治疗前后血小板数量在统计学比较上无差异（26．10±13．93×10^9／L vs 51．85±39．28×10^9／L，P=0．138）。给予根除Hp治疗的20例患者中，治疗有效病例16例（80％），无效4例（20％）。根除Hp治疗有效患者中血小板开始上升的时间为3—28d，中位时间为6d；维持有效的时间为17—125d，中位时间为75d。结论本临床观察中，CITP患者合并Hp感染率为58．82％，采用根除Hp治疗的根除率为55％，根除Hp治疗有助于Hp感染的CITP患者血小板恢复。
